BRPI0517947A - composto de piridazina, composições e métodos - Google Patents

composto de piridazina, composições e métodos

Info

Publication number
BRPI0517947A
BRPI0517947A BRPI0517947-5A BRPI0517947A BRPI0517947A BR PI0517947 A BRPI0517947 A BR PI0517947A BR PI0517947 A BRPI0517947 A BR PI0517947A BR PI0517947 A BRPI0517947 A BR PI0517947A
Authority
BR
Brazil
Prior art keywords
compositions
methods
pyridazine compound
making
pyridazine compounds
Prior art date
Application number
BRPI0517947-5A
Other languages
English (en)
Inventor
D Martin Watterson
Eldik Linda Van
Jacques Haiech
Marcel Hibert
Jean-Jacques Bourguignon
Anastasia Velentza
Wenhui Hu
Magdelena Zasadzki
Original Assignee
Univ Northwestern
Univ Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern, Univ Pasteur filed Critical Univ Northwestern
Publication of BRPI0517947A publication Critical patent/BRPI0517947A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

COMPOSTOS DE PIRIDAZINA, COMPOSIçõES E MéTODOS. A invenção relaciona-se a novos compostos químicos, composições e métodos de fazer e usar os mesmos. Em particular, a invenção fornece compostos de piridazina e/ou derivados heterocíclicos relacionados, composições que compreendem os mesmos, e métodos de fazer e usar os compostos de piridazina e/ou derivados heterocíclicos relacionados e composições que compreende os mesmos, para modulação das vias celulares (por exemplo, vias de transduçáo de sinal), para o tratamento ou prevenção de doenças inflamatórias (por exemplo, doença de Alzheimer), para pesquisa, rastreamento de medicamento, e aplicações terapêuticas.
BRPI0517947-5A 2004-11-02 2005-11-02 composto de piridazina, composições e métodos BRPI0517947A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62434604P 2004-11-02 2004-11-02
US72309005P 2005-10-03 2005-10-03
US72312405P 2005-10-03 2005-10-03
PCT/US2005/039541 WO2006050389A2 (en) 2004-11-02 2005-11-02 Pyridazine compounds, compositions and methods

Publications (1)

Publication Number Publication Date
BRPI0517947A true BRPI0517947A (pt) 2008-10-21

Family

ID=36319787

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517947-5A BRPI0517947A (pt) 2004-11-02 2005-11-02 composto de piridazina, composições e métodos

Country Status (11)

Country Link
US (4) US8367672B2 (pt)
EP (2) EP2592075B1 (pt)
JP (1) JP5337375B2 (pt)
CN (1) CN101087766B (pt)
AU (1) AU2005302225B2 (pt)
BR (1) BRPI0517947A (pt)
CA (1) CA2589106C (pt)
ES (2) ES2441718T3 (pt)
IL (1) IL182765A (pt)
MX (1) MX2007005247A (pt)
WO (1) WO2006050389A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
EP2264014A1 (en) * 2001-08-31 2010-12-22 Université Louis Pasteur Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP2592075B1 (en) 2004-11-02 2015-04-29 Northwestern University Pyridazine compounds for the treatment of inflammatory diseases
EP2233470B1 (en) 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
US20100168120A1 (en) * 2006-04-28 2010-07-01 Neuromedix Inc. Salts of pyridazine compounds
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
MX2008013843A (es) 2006-04-28 2008-11-10 Univ Northwestern Formulaciones que contienen compuestos de piridazina para tratar enfermedades neuroinflamatorias.
ES2375872T3 (es) 2006-05-29 2012-03-07 High Point Pharmaceuticals, Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperacin-1-il)-piridacina, sus sales y solvatos, y su uso como antagonista del receptor h3 de la histamina.
WO2008094208A2 (en) 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics
JP5603770B2 (ja) * 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
PE20120061A1 (es) 2008-12-19 2012-02-19 Boehringer Ingelheim Int Derivados de pirimidina como antagonistas del receptor ccr2
US20100227793A1 (en) * 2009-03-04 2010-09-09 Scott Thomas Brady Compositions and Methods for Treating Amyotrophic Lateral Sclerosis
EA024397B1 (ru) 2009-12-17 2016-09-30 Сентрекшн Терапьютикс Корпорейшн Новые антагонисты рецептора ccr2 и их применение
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5647339B2 (ja) 2010-05-17 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２アンタゴニスト及びこれらの使用
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
WO2011156901A2 (en) * 2010-06-17 2011-12-22 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of multiple sclerosis
WO2012012891A1 (en) * 2010-07-29 2012-02-02 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of arthritis
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
EP2968322B1 (en) 2013-03-15 2018-12-26 The Trustees of Columbia University in the City of New York Map kinase modulators and uses thereof
JP6917910B2 (ja) 2015-07-02 2021-08-11 セントレクシオン セラピューティクス コーポレイション （４−（（３ｒ，４ｒ）−３−メトキシテトラヒドロ−ピラン−４−イルアミノ）ピペリジン−１−イル）（５−メチル−６−（（（２ｒ，６ｓ）−６−（ｐ−トリル）テトラヒドロ−２ｈ−ピラン−２−イル）メチルアミノ）ピリミジン−４イル）メタノンクエン酸塩
CN109071524A (zh) * 2016-01-15 2018-12-21 布里格姆及妇女医院股份有限公司 作为eaat2活化剂的哒嗪衍生物
CA3195960A1 (en) * 2020-10-23 2022-04-28 Madrigal Pharmaceuticals, Inc. Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL92451C (pt) * 1955-08-19
US3464988A (en) * 1968-01-11 1969-09-02 Bristol Myers Co 3-hydrazinobenzo(h)cinnolines and 3 - hydrazinobenzocyclohepta-(5,6-c)pyridazines
GB1345880A (en) 1971-06-18 1974-02-06 Cepbepe Pyridazine derivatives
FR2510998B1 (fr) * 1981-08-07 1986-01-10 Sanofi Sa Nouveaux derives amines de la pyridazine, leur procede de preparation et les medicaments, a action desinhibitrice, qui en comportent
FR2511366A1 (fr) * 1981-08-11 1983-02-18 Sanofi Sa Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
DE3217325A1 (de) 1982-05-08 1983-11-10 Hoechst Ag, 6230 Frankfurt 3-amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre herstellung und ihre verwendung
FR2540113A1 (fr) * 1983-01-27 1984-08-03 Sanofi Sa Acides derives de la pyridazine actifs sur le systeme nerveux central
JPS59212480A (ja) * 1983-05-17 1984-12-01 Nippon Soda Co Ltd ピリダジン誘導体及び除草剤
AU578496B2 (en) * 1984-11-01 1988-10-27 Smith Kline & French Laboratories Limited Tricyclic heterocyclic compounds
DE3517617A1 (de) * 1985-05-15 1986-11-20 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
ES8802151A1 (es) * 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
JPH0650381B2 (ja) 1985-08-05 1994-06-29 富士写真フイルム株式会社 ハロゲン化銀カラ−感光材料の処理方法
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
FR2601011B1 (fr) * 1986-07-03 1988-10-28 Sanofi Sa Nouveaux derives tricycliques agonistes des recepteurs cholinergiques et medicaments en contenant
JP2531678B2 (ja) 1987-05-27 1996-09-04 吉富製薬株式会社 トリアゾロピリダジン誘導体
EP0351435B1 (en) * 1987-11-02 1993-08-04 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyridazine compounds and their medicinal uses
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
ES2114654T3 (es) 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
US5484940A (en) * 1994-11-28 1996-01-16 Grant; Francine S. Substituted 3-indolyl-5-pyrazolone compounds
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
GB9707693D0 (en) 1997-04-16 1997-06-04 Smithkline Beecham Plc Novel method of treatment
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
EP1317449B1 (en) 2000-09-15 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1757600A2 (en) 2000-10-13 2007-02-28 NeuroSearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2003014110A1 (fr) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Derive de benzazepine, son procede de preparation et d'utilisation
EP2264014A1 (en) 2001-08-31 2010-12-22 Université Louis Pasteur Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP4607458B2 (ja) * 2002-02-05 2011-01-05 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規なアリールおよびへテロアリールピペラジン
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
AU2004259263B2 (en) 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
US7378418B2 (en) 2003-12-19 2008-05-27 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TW200530246A (en) 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
JP4230380B2 (ja) 2004-02-24 2009-02-25 三菱電機株式会社 レンズクリーニングディスク
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP2592075B1 (en) 2004-11-02 2015-04-29 Northwestern University Pyridazine compounds for the treatment of inflammatory diseases
US20090029958A1 (en) 2006-03-08 2009-01-29 Lilian Alcaraz Phenethanolamine derivatives as beta2 adrenoreceptor agonists
US20100168120A1 (en) 2006-04-28 2010-07-01 Neuromedix Inc. Salts of pyridazine compounds
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
MX2008013843A (es) * 2006-04-28 2008-11-10 Univ Northwestern Formulaciones que contienen compuestos de piridazina para tratar enfermedades neuroinflamatorias.
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007127475A2 (en) 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
US7732445B2 (en) * 2006-07-21 2010-06-08 Northwestern University Myosin light chain kinase inhibitor compounds, compostions and related methods of use
AU2008223066A1 (en) 2007-03-02 2008-09-12 Northwestern University Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders
US20100130442A1 (en) * 2007-05-07 2010-05-27 Raj Wadgaonkar Lung Injury Treatment

Also Published As

Publication number Publication date
CA2589106A1 (en) 2006-05-11
EP1812408A2 (en) 2007-08-01
US9527819B2 (en) 2016-12-27
IL182765A (en) 2013-05-30
US20150175555A1 (en) 2015-06-25
EP1812408A4 (en) 2012-05-02
WO2006050389A2 (en) 2006-05-11
MX2007005247A (es) 2008-03-13
CA2589106C (en) 2015-07-21
JP5337375B2 (ja) 2013-11-06
EP1812408B1 (en) 2013-10-09
US20120245125A1 (en) 2012-09-27
ES2543813T3 (es) 2015-08-24
JP2008518958A (ja) 2008-06-05
IL182765A0 (en) 2007-07-24
CN101087766B (zh) 2011-09-07
AU2005302225B2 (en) 2012-05-24
WO2006050389A3 (en) 2006-07-06
US8933076B2 (en) 2015-01-13
US9663493B2 (en) 2017-05-30
AU2005302225A1 (en) 2006-05-11
US20160326139A1 (en) 2016-11-10
CN101087766A (zh) 2007-12-12
ES2441718T3 (es) 2014-02-06
US20080318899A1 (en) 2008-12-25
US8367672B2 (en) 2013-02-05
EP2592075A1 (en) 2013-05-15
EP2592075B1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
BRPI0517947A (pt) composto de piridazina, composições e métodos
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20055129L (no) Fenylsubstituerte karboksylsyrer
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
NO20055731L (no) Cannabinoide reseptorligander og deres anvendelse
NO20084362L (no) Difenylazetidinon derivater inneholdende kolesterol absorbsjonsinhibitor aktivitet
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
BRPI0607897A2 (pt) compostos oxindol e sua utilização como agentes terapêuticos
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NO20053792L (no) Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
BRPI0511350A (pt) composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
DK3889142T3 (da) 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NORTHWESTERN UNIVERSITY (US) , UNIVERSITE DE STRAS

Free format text: TRANSFERIDO POR INCORPORACAO DE: UNIVERSITE LOUIS PASTEUR DE STRASBOURG.

B25A Requested transfer of rights approved

Owner name: NORTHWESTERN UNIVERSITY (US) , UNIVERSITE DE STRAS

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: UNIVERSITE DE STRASBOURG E NORTHWESTERN UNIVERSITY

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 237/00 , C07D 237/02 , C07D 403/00 , C07D 405/00 , C07D 409/00 , A01N 43/58 , A61K 31/50 , A61K 31/4965

Ipc: C07D 237/00 (2006.01), C07D 237/02 (2006.01), C07D

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2642 DE 24-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.